The Role of B Cells in Primary Progressive Multiple Sclerosis
Open Access
- 7 June 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Neurology
Abstract
The success of ocrelizumab in reducing confirmed disability accumulation in primary progressive multiple sclerosis (PPMS) via CD20-targeted depletion implicates B cells as causal agents in the pathogenesis of PPMS. This review explores the possible mechanisms by which B cells contribute to disease progression in PPMS, specifically exploring cytokine production, antigen presentation, and antibody synthesis. B cells may contribute to disease progression in PPMS through cytokine production, specifically GM-CSF and IL-6, which can drive naïve T-cell differentiation into pro-inflammatory Th1/Th17 cells. B cell production of the cytokine LT-α may induce follicular dendritic cell production of CXCL13 and lead indirectly to T and B cell infiltration into the CNS. In contrast, production of IL-10 by B cells likely induces an anti-inflammatory effect that may play a role in reducing neuroinflammation in PPMS. Therefore, reduced production of IL-10 may contribute to disease worsening. B cells are also capable of potent antigen presentation and may induce pro-inflammatory T-cell differentiation via cognate interactions. B cells may also contribute to disease activity via antibody synthesis, although it's unlikely the benefit of ocrelizumab in PPMS occurs via antibody decrement. Finally, various B cell subsets likely promulgate pro- or anti-inflammatory effects in MS.Keywords
This publication has 119 references indexed in Scilit:
- Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trialThe Lancet Neurology, 2013
- B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cellsThe Journal of Experimental Medicine, 2012
- Inflammatory Cortical Demyelination in Early Multiple SclerosisThe New England Journal of Medicine, 2011
- Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)British Journal of Pharmacology, 2011
- Characterization of a rare IL-10–competent B-cell subset in humans that parallels mouse regulatory B10 cellsBlood, 2011
- B‐cell activation influences T‐cell polarization and outcome of anti‐CD20 B‐cell depletion in central nervous system autoimmunityAnnals of Neurology, 2010
- Atacicept: targeting B cells in multiple sclerosisTherapeutic Advances in Neurological Disorders, 2010
- Changes in B- and T-Lymphocyte and Chemokine Levels With Rituximab Treatment in Multiple SclerosisArchives of Neurology, 2010
- The relation between inflammation and neurodegeneration in multiple sclerosis brainsBrain, 2009
- Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patientsJournal of Neuroimmunology, 2006